Renal impairment: Baclofen is excreted primarily unchanged by the kidneys; patients with reduced kidney function should receive a lower dose with careful upward titration and monitoring for signs of toxicity (drowsiness, confusion, weakness).Hepatic impairment: limited specific data exist; Baclofen should be used with caution and liver function monitored where relevant, since a minor portion of the dose is metabolized in the liver.Elderly patients: older adults may be more sensitive to the sedative and confusional effects of Baclofen; a lower starting dose and slower titration are advisable, with close monitoring.Pregnant and breastfeeding women: see Pregnancy and Lactation for detailed guidance.Pediatric patients: safety and efficacy of oral Baclofen have not been established in children under 12 years; see Pediatric Uses.Pediatric UsesThe safety and efficacy of oral Baclofen have not been established in children below 12 years of age for the standard tablet formulation. When Baclofen is used in children for spasticity related to cerebral palsy or other central nervous system conditions, this is generally considered an off-label, specialist-guided use, with dosing individualized by a pediatric neurologist or specialist based on the child's age, weight, and response, starting at a low dose and titrating gradually, similar in principle to adult titration but at markedly lower doses. As in adults, Baclofen must never be stopped abruptly in a child who has been taking it regularly, because of the risk of withdrawal symptoms; any discontinuation should be gradual and supervised by the treating specialist.